ZOVIRAX DUAL Rx/OTC STATUS SUGGESTED
This article was originally published in The Tan Sheet
Executive Summary
ZOVIRAX DUAL Rx/OTC STATUS SUGGESTED as a way of maintaining insurance coverage for the medication in April 29 comments by the American Medical Women's Association supporting the switch of the orally administered genital herpes drug. Indicating that increased cost to patients of an OTC version of Zovirax (acyclovir) may be an issue in the switch process, AMWA President Kathryn Bemmann, MD, suggested that "Medicaid and insurance coverage for the medication...be continued for individuals who are currently using 'covered' prescriptions." She added that "perhaps a dual status of OTC and Rx could be maintained."
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
People In Brief
Perrigo promotes in pricing, planning
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: